1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Market Spotlight: Sarcoma

Market Spotlight: Sarcoma

  • April 2018
  • 40 pages
  • ID: 5336392
  • Format: PDF

Summary

Table of Contents

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.ts.
 
Key Takeaways 
Datamonitor Healthcare estimates that in 2016, there were approximately 403,000 incident cases of sarcoma worldwide, and forecasts that number to increase to 473,700 incident cases by 2025. 

Worldwide in 2016, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (~85%), while a smaller proportion were osteosarcomas and other malignant bone tumors (~15%). 
The approved drugs in the sarcoma space focus on targets such as tumor necrosis factor-alpha, microtubules, platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT/c-KIT, and DNA. All of the approved drugs are administered via the intravenous route, except for one drug which is available in an oral formulation. 

The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are  administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intratumoral, and topical formulations. 

High impact upcoming events in the sarcoma space include topline Phase II trial results for NY-ESO-1(C259), and topline Phase III trial results for TRC105 and Nirogacestat. 

There have been 14 licensing and asset acquisition deals involving sarcoma drugs during 2013–18. The licensing agreement between Adaptimmune and GlaxoSmithKline in 2014 for $1,150m to develop and commercialize NY-ESO-1(C259) was the largest deal. 
Votrient sales ranked highest among drugs approved for sarcoma during 2012–16, and its sales are forecasted to remain high through 2022. 


The distribution of clinical trials across Phase I–IV indicates that the majority of trials for sarcoma have been in the early and midphases of development, with 90.7% of trials in Phase I–II, and only 9.3% in Phase III–IV. 
The US has a substantial lead in the number of sarcoma clinical trials globally, while France leads the major EU markets. Clinical trial activity in the sarcoma space is dominated by completed trials. 

Merck&Co and Novartis have the highest number of completed clinical trials for sarcoma, with 14 trials each. 
Merck&Co leads industry sponsors with the highest number of clinical trials for sarcoma, followed by Novartis and Pfizer.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Leiomyosarcoma - Pipeline Review, H1 2019

Leiomyosarcoma - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Leiomyosarcoma - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H1 2019, provides an overview of ...

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide ...

Anal Cancer - Pipeline Review, H1 2019

Anal Cancer - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Anal Cancer - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2019, provides an overview of the Anal ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on